PEOPLE - Monogram Biosciences makes appointment:
This article was originally published in Clinica
Executive Summary
Monogram Biosciences has promoted Gordon Parry to the position of vice-president, R&D, oncology. Dr Parry will have responsibility for Monogram's oncology programmes, including the further development of the San Francisco, California firm's VeraTag technology and the first product based on that platform - the HERMark breast cancer assay. Dr Parry joined Monogram in 2007; before that, he worked for 12 years at Berlex Biosciences where he was the department head of the cancer research department. Previously, he held a variety of research positions in academia, including ten years at the University of California's Lawrence Berkeley Laboratory. He is also an advisory council member for the California Breast Cancer Research Program.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.